These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10049294)

  • 21. The intestinal permeation of didanosine from granules containing microspheres using the everted gut sac model.
    da Silva CF; Severino P; Martins F; Chaud MV; Santana MH
    J Microencapsul; 2009 Sep; 26(6):523-8. PubMed ID: 19545225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
    Pruvost A; Negredo E; Benech H; Theodoro F; Puig J; Grau E; García E; Moltó J; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2005 May; 49(5):1907-14. PubMed ID: 15855513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice.
    Manouilov KK; Xu ZS; Boudinot FD; Schinazi RF; Chu CK
    Antiviral Res; 1997 May; 34(3):91-9. PubMed ID: 9191016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
    De Forni D; Stevens MR; Lori F
    Br J Pharmacol; 2010 Oct; 161(4):830-43. PubMed ID: 20860662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
    Becher F; Landman R; Mboup S; Kane CN; Canestri A; Liegeois F; Vray M; Prevot MH; Leleu G; Benech H
    AIDS; 2004 Jan; 18(2):181-7. PubMed ID: 15075534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
    Hasegawa T; Juni K; Saneyoshi M; Kawaguchi T
    Biol Pharm Bull; 1996 Apr; 19(4):599-603. PubMed ID: 8860966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Damle B; Smith E; Wiznia A; Acosta EP
    Antivir Ther; 2002 Dec; 7(4):267-70. PubMed ID: 12553481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability study of two oral formulations of didanosine in healthy volunteers.
    Schramm Andrade S; Kano EK; de Lima Souza Brioschi TM; Koono EE; dos Reis Serra CH; Porta V
    Arzneimittelforschung; 2006; 56(5):359-64. PubMed ID: 16821647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using Gaussian-like input rate function in the two-compartment model. Formulation and application to analysis of didanosine plasma concentration in two Japanese hemophiliacs.
    Tatsunami S; Sako K; Kuwabara R; Yamada K
    Int J Clin Pharmacol Res; 1998; 18(3):129-35. PubMed ID: 9825269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
    Shelton MJ; Mei H; Hewitt RG; Defrancesco R
    Antimicrob Agents Chemother; 2001 Jan; 45(1):298-300. PubMed ID: 11120981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
    Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S
    AIDS; 2013 Mar; 27(5):761-8. PubMed ID: 23719348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD; Fischl MA; Shelton MJ; Cox SR; Driver M; DeRemer M; Freimuth WW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Penetration of didanosine in semen of HIV-1-infected men.
    Cruciani M; Liuzzi G; Chirianni A; Audagnotto S; Bonora S; Di Biagio A; Sinicco A; Bassetti M; Gatti G
    J Antimicrob Chemother; 2006 Jun; 57(6):1244-7. PubMed ID: 16556633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired absorption of rifabutin by concomitant administration of didanosine.
    Marzolini C; Chave JP; Telenti A; Brenas-Chinchon L; Biollaz J
    AIDS; 2001 Nov; 15(16):2203-4. PubMed ID: 11684946
    [No Abstract]   [Full Text] [Related]  

  • 38. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
    Abreu T; Plaisance K; Rexroad V; Nogueira S; Oliveira RH; Evangelista LA; Rangel R; Silva IS; Knupp C; Lambert JS
    Antimicrob Agents Chemother; 2000 May; 44(5):1375-6. PubMed ID: 10770783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
    Bruzzese VL; Gillum JG; Israel DS; Johnson GL; Kaplowitz LG; Polk RE
    Antimicrob Agents Chemother; 1995 May; 39(5):1050-3. PubMed ID: 7625787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets.
    DePestel DD; Kazanjian PH; Cinti SK; Kauffman CA; Carver PL
    Pharmacotherapy; 2004 Nov; 24(11):1539-45. PubMed ID: 15537559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.